fever
neutropenia
frequent
problem
patient
hematolog
malign
common
caus
nonmalign
morbid
mortal
patient
group
infecti
etiolog
identifi
percent
febril
neutropen
episod
despit
diagnost
gap
studi
guidelin
mere
presum
bacteri
fungal
microorgan
caus
neutropen
fever
extens
look
possibl
viral
etiolog
sinc
respiratori
virus
known
common
caus
fever
gener
popul
clinic
present
viral
infect
often
specif
neutropen
patient
diagnost
screen
respiratori
virus
seem
ration
patient
present
neutropen
fever
children
grow
evid
neutropen
fever
frequent
associ
respiratori
viral
infect
moreov
stem
cell
transplant
sct
patient
virus
recogn
frequent
caus
posttranspl
fever
last
decad
molecular
techniqu
polymeras
chain
reaction
pcr
revolution
diagnosi
viral
infect
pcr
enabl
rapid
highli
sensit
detect
larg
number
respiratori
virus
includ
difficult
cultur
human
bocaviru
hbov
human
metapneumoviru
hmpv
patient
hematolog
malign
pcr
shown
far
sensit
viral
cultur
studi
look
viral
preval
neutropen
fever
studi
perform
look
role
respiratori
virus
neutropen
fever
adult
hematolog
malign
assess
use
screen
respiratori
virus
onset
neutropenia
paper
describ
prospect
studi
perform
academ
medic
centr
amc
act
tertiari
referr
centr
netherland
data
obtain
longitudin
cohort
studi
adult
hematolog
ward
amc
perform
novemb
april
patient
elig
inclus
chemotherapyinduc
signific
neutropenia
ie
day
expect
patient
could
includ
everi
success
neutropen
episod
assum
latter
episod
follow
full
recoveri
peripher
blood
neutrophil
count
patient
discharg
hospit
episod
three
type
respiratori
specimen
nasal
swab
pharyng
swab
throat
gurgl
collect
differ
time
point
upon
admiss
ie
around
onset
chemotherapi
deep
neutropenia
day
onset
chemotherapi
present
start
neutropen
fever
differ
time
point
label
phase
phase
b
phase
c
respect
fever
defin
singl
temperatur
sustain
temperatur
one
hour
patient
symptom
sign
admiss
regist
case
record
form
materi
analyz
quantit
real
time
multiplex
pcr
cover
follow
virus
influenzaviru
infa
b
infb
enteroviru
ev
adenoviru
adv
respiratori
syncyti
viru
rsv
rhinoviru
rv
humanmetapneumoviru
hmpv
parainfluenzaviru
humanparechoviru
hpev
humancoronaviru
hcov
humanbocaviru
hbov
done
end
studi
henc
treat
physician
awar
studi
result
patient
treatment
local
ethic
committe
approv
studi
particip
patient
provid
written
inform
consent
enter
studi
studi
prospect
includ
patient
develop
total
episod
neutropenia
episod
neutropen
fever
studi
ten
episod
sampl
onset
chemotherapi
could
perform
mere
sampl
neutropenia
collect
includ
neutropen
patient
phase
develop
neutropen
fever
phase
c
n
develop
fever
day
onset
chemotherapi
therefor
pass
sampl
phase
b
patient
characterist
shown
tabl
acut
myeloid
leukemia
frequent
diagnosi
follow
multipl
myeloma
relaps
diffus
larg
cell
nonhodgkin
lymphoma
patient
treat
intens
chemotherapi
myeloabl
chemotherapi
follow
autolog
stem
cell
rescu
allogen
stem
cell
transplant
limit
number
patient
treat
reduc
intens
condit
follow
allogen
stem
cell
transplant
includ
respiratori
tract
sign
symptom
defin
rhinorrhoea
cough
sneez
sore
throat
except
neutropen
phase
dyspnea
crackl
wheez
auscult
sore
throat
neutropenia
consid
infecti
respiratori
symptom
sinc
usual
associ
chemotherapyinduc
mucos
respiratori
tract
complaint
present
patient
upon
admiss
phase
patient
neutropenia
phase
b
patient
neutropen
fever
phase
c
probabl
clinic
diagnosi
neutropen
fever
establish
treat
physician
febril
patient
preval
clinic
diagnos
central
venou
cathet
relat
infect
neutropen
coliti
pneumonia
contrast
clinic
diagnosi
patient
neutropen
fever
abnorm
imag
possibl
consist
lower
respiratori
tract
infect
diagnost
result
shown
tabl
start
chemotherapi
phase
viral
nucleic
acid
detect
patient
neutropen
patient
without
fever
group
b
fever
phase
c
respiratori
viru
detect
pcr
distribut
viral
speci
found
differ
group
describ
tabl
rv
frequent
detect
viru
follow
hbov
hcov
infa
b
piv
present
test
sampl
substanti
differ
distribut
specif
viral
speci
observ
group
viral
posit
show
season
pattern
group
patient
respiratori
symptom
associ
higher
preval
respiratori
virus
compar
asymptomat
patient
resp
vs
look
differ
sampl
type
nasal
swab
posit
rate
compar
throat
swab
throat
gurgl
differ
nasal
swab
throat
swab
statist
signific
p
chi
squar
test
multipl
sampl
taken
one
sampl
posit
pair
sampl
longitudin
analys
prospect
sampl
show
virus
found
start
chemotherapi
still
present
neutropenia
one
patient
anoth
patient
without
neutropen
fever
case
concern
rv
clinic
manag
neutropen
fever
remain
challeng
treatment
hematolog
malign
patient
symptom
often
nonspecif
etiolog
infect
frequent
establish
present
studi
perform
longitudin
prospect
studi
address
role
respiratori
virus
caus
neutropen
fever
assess
clinic
relev
diagnost
screen
respiratori
virus
cours
neutropenia
data
collect
studi
support
promin
etiolog
role
respiratori
virus
develop
neutropen
fever
patient
respiratori
virus
detect
exhibit
respiratori
symptom
sign
patient
without
respiratori
virus
could
possibl
explain
alter
nonspecif
symptomatolog
immunocompromis
set
also
differ
frequenc
viru
detect
respiratori
specimen
obtain
neutropenia
episod
neutropen
fever
moreov
respiratori
virus
present
specimen
obtain
onset
neutropenia
seldom
remain
detect
follow
specimen
collect
neutropenia
observ
suggest
elabor
diagnost
screen
respiratori
virus
febril
neutropenia
clinic
use
howev
note
viru
speci
detect
sampl
mostli
speci
consid
less
pathogen
eg
rv
hbov
hcov
exampl
inf
rare
found
latter
fact
could
partli
explain
increas
awar
reinforc
prevent
measur
threat
newli
appear
influenza
strain
consid
type
sampl
observ
nasal
swab
perform
better
throat
swab
knowledg
studi
compar
nasal
swap
sampl
techniqu
test
respiratori
viru
pcr
adult
none
perform
adult
hematolog
malign
studi
show
superior
perform
nasal
swab
compar
pharyng
swab
although
use
two
simultan
techniqu
result
highest
yield
posit
result
find
support
latter
find
suggest
sole
use
pharyng
swab
avoid
viral
detect
hematolog
patient
shown
tabl
complet
set
nasal
swab
pharyng
swab
throat
gurgl
obtain
patient
could
possibl
introduc
bia
compar
sampl
method
howev
sinc
everi
sampl
obtain
simultan
least
one
sampl
think
bia
small
although
routin
screen
respiratori
warrant
subject
respiratori
symptom
viral
test
use
determin
etiolog
complaint
start
barrier
precaut
start
adequ
treatment
case
influenza
patient
test
lower
respiratori
tract
sampl
favor
upper
respiratori
sampl
studi
follow
limit
studi
perform
rel
small
studi
group
repres
limit
time
span
circul
pathogen
virus
differ
year
therefor
find
studi
directli
extrapol
futur
viral
respiratori
season
clinic
set
second
limit
rise
new
pandem
much
awar
prevent
measur
around
respiratori
viru
ie
hand
hygien
ward
vaccin
among
staff
gener
popul
may
reduc
spread
influenza
respiratori
viru
hematolog
ward
conclus
prospect
studi
support
hypothesi
respiratori
virus
play
import
role
develop
neutropen
fever
thu
screen
respiratori
viru
neutropenia
use
author
declar
compet
interest
rj
bb
js
cv
contribut
develop
research
protocol
gather
inform
consent
patient
sampl
clinic
inform
done
rj
bb
pcr
analysi
statist
analysi
perfomend
sk
rm
rj
write
manuscript
complet
rj
bb
md
cv
author
read
approv
final
manuscript
